Cyclophosphamide
Unresectable Locally Advanced or Metastatic Disease
Beijing BiotechSmall moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the Unresectable Locally Advanced or Metastatic Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Beijing Biotech | Phase 1/2 | CC |
Eb-Dnk101 Dual-Targeting Car-Nk Cells Beijing Biotech | Phase 1/2 | CC |
Eb-Dnk102 Dual-Targeting Car-Nk Cells Beijing Biotech | Phase 1/2 | CC |
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →